Integrity Alliance LLC. Makes New $445,000 Investment in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Integrity Alliance LLC recently acquired a new position in Vertex Pharmaceuticals by purchasing 917 shares valued at approximately $445,000.
• Vertex Pharmaceuticals reported a net margin of 31.86% and a year-over-year revenue increase of 11.3%, posting $4.52 EPS in its latest quarterly earnings.
• Recent price targets for Vertex Pharmaceuticals from analysts range from $455.00 to $530.00, with a consensus rating of "Moderate Buy".

Integrity Alliance LLC. bought a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 917 shares of the pharmaceutical company's stock, valued at approximately $445,000.

A number of other large investors have also recently bought and sold shares of VRTX. Activest Wealth Management bought a new position in Vertex Pharmaceuticals in the first quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd lifted its holdings in Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock worth $27,000 after acquiring an additional 45 shares during the last quarter. Mascagni Wealth Management Inc. bought a new position in Vertex Pharmaceuticals in the fourth quarter worth about $31,000. Mpwm Advisory Solutions LLC bought a new position in Vertex Pharmaceuticals in the fourth quarter worth about $40,000. Finally, SJS Investment Consulting Inc. lifted its holdings in Vertex Pharmaceuticals by 46.2% in the first quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company's stock worth $46,000 after acquiring an additional 30 shares during the last quarter. Institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $394.53 on Friday. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The firm has a market capitalization of $101.15 billion, a PE ratio of 28.20 and a beta of 0.44. The company's 50 day simple moving average is $422.66 and its 200 day simple moving average is $453.56.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same quarter last year, the business earned ($12.83) earnings per share. The business's revenue for the quarter was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VRTX has been the topic of a number of recent research reports. BMO Capital Markets set a $530.00 target price on shares of Vertex Pharmaceuticals and gave the stock an "outperform" rating in a report on Tuesday, August 5th. Stifel Nicolaus cut their price target on Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating on the stock in a report on Tuesday, August 5th. Raymond James Financial initiated coverage on Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They set a "market perform" rating on the stock. JPMorgan Chase & Co. lifted their price target on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an "overweight" rating in a report on Monday, July 14th. Finally, Erste Group Bank cut Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $496.05.

Insider Activity at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs acquired 5,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were acquired at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the purchase, the director directly owned 45,000 shares of the company's stock, valued at $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.20% of the stock is owned by corporate insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.